Skip to content
HowShorted

Accelerate Diagnostics, Inc short interest in 2024

In 2024, Accelerate Diagnostics, Inc's disclosed short interest ran from 3.08% of shares outstanding on 12 Jan 2024 to 1.62% on 31 Dec 2024, a change of -1.46 percentage points. The year's high was 3.08% on 12 Jan 2024 and its low 1.35% on 28 Mar 2024, averaging 2.16% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 24.74 days on 12 Jan 2024. Full history: Accelerate Diagnostics, Inc.

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025

Aggregate net short position time series for Accelerate Diagnostics, Inc in 2024

2024 in figures

Start of year
3.08% (12 Jan 2024)
End of year
1.62% (31 Dec 2024)
Change
-1.46 pp
High
3.08% (12 Jan 2024)
Low
1.35% (28 Mar 2024)
Average
2.16%
Highest days to cover
24.74 (12 Jan 2024)
SEC filings marked
9

Every report in 2024

Accelerate Diagnostics, Inc short interest in 2024
SettlementShort interestDays to coverFilings since previous
12 Jan 20243.08%24.74results (8-K)
31 Jan 20242.57%1.00
15 Feb 20242.39%3.82
29 Feb 20242.06%4.79
15 Mar 20241.98%4.08
28 Mar 20241.35%4.67
15 Apr 20241.72%4.4210-K filed, results (8-K)
30 Apr 20241.49%7.97
15 May 20241.79%11.06results (8-K), 10-Q filed
31 May 20241.96%2.39
14 Jun 20242.55%9.54
28 Jun 20242.90%11.13
15 Jul 20242.80%15.50
31 Jul 20242.77%18.59
15 Aug 20242.33%7.4410-Q filed, results (8-K)
30 Aug 20242.26%11.09
13 Sep 20241.98%6.16
30 Sep 20242.01%8.26
15 Oct 20242.00%7.55
31 Oct 20242.16%7.68
15 Nov 20242.10%8.9210-Q filed, results (8-K)
29 Nov 20242.10%12.58
13 Dec 20241.97%6.02
31 Dec 20241.62%3.58

See also: Accelerate Diagnostics, Inc's full history · most shorted US stocks of 2024 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.